Amneal buying AvKare, drugmaker to the feds 

Chirag Patel and Chintu Patel, co-founders of Amneal, regained control of the company in August. It has now struck a deal for AvKare, known as R&S Northeast, which sells private label drugs to the federal government that it sources through 50 vendors. (Amneal)

Just months after a C-suite shakeup at Amneal, the generics company has struck a $220 million deal that will not only fill capacity and boost its generics business but is set to disrupt the contract manufacturing market. That is because it is buying a majority stake in AvKare, which sources the private-label drugs it sells the government through dozens of contractors. 

Amneal says it is buying a 65.1% stake in the Fountain Run, Kentucky-based business which will become a standalone subsidiary of Amneal. It says the deal sets the enterprise value of AvKare at $340 million. AvKare does business as R&S Northeast. 

AvKare sells its own private label generic drugs primarily to the Departments of Defense and Veterans Affairs. It buys most of those from more than 50 vendors. 


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

RELATED: Paul Bisaro vaulted now-struggling Amneal to top generics ranks—now, he and his handpicked CEO are out

Amneal founders Chirag Patel and Chintu Patel said the deal is in line with the strategy they set out for the company when the re-joined Amneal as Co-CEOs in August. It opens up new markets, allowing it to use its manufacturing network to produce drugs for the growing federal government market, the Patels said in a statement attributed to both. 

“While we remain extremely focused on organic growth, we also recognized that M&A would be a key element of our growth story, and that we would pursue the right opportunities that strategically fit our business,” the statement says of the Bridgewater, New Jersey-based Amneal.  

RELATED: Bisaro steers Impax to $6.4B Amneal merger, creating fifth-largest U.S. generics company

The brothers returned to running the struggling generics maker in August after the board ousted Paul Bisaro, Amneal’s executive chairman, and Rob Stewart, the president and CEO who followed Bisaro from Allergan. Bisaro, who had a record of building generics companies through M&A, was running Impax Labs when it bought Amneal in 2017 for $6.4 billion. 

But the beefed-up company, which has a portfolio of more than 300 drugs, floundered as the U.S. generics market softened. Its stock price dropped from a high of $24.25 per share in August 2018 to $3.08 when Bisaro was shown the door. Shares closed Tuesday at $3.50, down 1.69% after the news of the AvKare deal.

Suggested Articles

After early threats, the FDA finished reviewing the company's response to a citation for data manipulation and decided not to take any further action.

China is quickly getting back up to speed with API production but reports freight bottlenecks are slowing deliveries.

Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.